GEN Exclusives

More »

GEN News Highlights

More »
Oct 17, 2006

MSM and CAT Target Multispanning Membrane Proteins

  • Cambridge Antibody Technology (CAT) and MSM Protein Technologies aim at developing antibody-based drugs targeting multispanning membrane proteins. This drug discovery collaboration is a two-year research agreement in which CAT will fund MSM to use its technology on CAT’s behalf. The two companies will provide each other with access to their respective technology for drug discovery.

    “This relationship with CAT follows a pilot project between CAT and MSM that demonstrated the synergy of our technologies for the successful selection of functional antibodies against multispanning membrane proteins,” points out Davis Farmer, MSM's chairman.

    Under the terms of the agreement, MSM will apply its technology to display multispanning membrane proteins to select antibodies from CAT libraries against a number of CAT- and MSM-nominated targets. CAT will pay MSM to conduct discovery work on CAT’s behalf and both companies will have obligations to pay milestones and royalties to one another upon the successful commercialization of any drugs resulting from the collaboration.

    “Multispanning membrane proteins comprise a major class of drug targets that includes G-protein coupled receptors, ion channels, and transporters,” explains Alex Duncan Ph.D., CAT's senior vp, discovery. “Together they represent roughly 70% of the targets for therapeutic drugs and are an important class of largely untapped protein targets for therapeutic antibodies.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?